Nextcure provides business update and reports full year 2023 financial results

Beltsville, md. – march 21, 2024, march 21, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update and reported full year 2023 financial results.

NXTC Ratings Summary

NXTC Quant Ranking